$160 billion investment arm of pharma giant acquires salmon sea lice-zapping firm

Deal is a major step for the 12-year-old aquaculture tech group.

John Arne Breivik, CEO of Stingray.
John Arne Breivik, CEO of Stingray.Photo: Joar Offerdal Vatlestad
Published 10 October 2024, 17:57Updated 10 October 2024, 18:26
Mergers & AcquisitionsFarmed salmonSea liceDiseasesNorway